Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (August 2015)
23 slides from Inspiremd's investor presentation, Aug 5, 2015
Slide 1: NYSE MKT: NSPR August 2015
NYSE MKT: NSPR August 2015
Slide 2: Forward Looking Statements
Forward Looking Statements 2 This presentation contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-look
Slide 3: InspireMD company snapshot
3 An emerging medical device company developing and commercializing advanced technology for interventional cardiology and other vascular procedures InspireMD NYSE MKT: NSPR Stock Price (8/3/15): $0.28 52 Week Range: $0.18 -$2.57 Average Volume: 1,248K Shares Outstanding (8/3/15): 78 M Market Capital
Slide 4: Investment Highlights
Investment Highlights 4 • 2015 return to revenue growth driven by the full launch of carotid platform through strategic distribution partnership with Penumbra, Inc. • Operating and financial realignment inline with development and growth initiatives. • Advancing into highly valued Neuroand Periphera
Slide 5: Leadership: Significant Track Records of Success
5 Leadership: Significant Track Records of Success EXECUTIVETEAM BOARD OF DIRECTORS Alan Milinazzo, President, CEO & Director • Medtronic • Boston Scientific Craig Shore,CFO • Pfizer • General Electric Dr. James Barry, COO • Boston Scientific • Howmedica Division of Pfizer Eli Bar, CTO • Nicast Gwen
Slide 6: InspireMD
inspireMiD
Slide 7: Technology: MicroNet Beyond Stenting
Technology: MicroNet™ 7 Beyond Stenting: MicroNetMesh for Embolic Prevention MicroNetPlatform Combines stent and embolic protection in a single device • Stent platform provides revascularization benefit • MicroNetthen acts as safety net by offering greater surface area coverage to prevent large debr
Slide 8: Large Addressable Markets Expanding the MicroNet Platform
Large Addressable Markets 8 Expanding the MicroNet™ Platform MGuard™ x$1.7B Market xCE Mark Cleared xCoronary AMI, SVG CGuard™ x$500M Market xCE Mark Cleared xCarotid NVGuard x$125M Flow Diversion Market x$550M Aneurysm Market x2016E CE Mark Planned Submission for Flow Diverter xNeurovascular PVGuar
Slide 9: Carotid Market Opportunity
Carotid Market Opportunity 9 An Enhanced Minimally Invasive Solution • Standard of care: Open surgery: Carotid EndArterectomy(CEA) • Current stents have not improved on CEA stroke rates (CREST) • Mesh covered stent category has the potential to convert CEA to CAS • CARENET 30-day and 6-mo data show
Slide 10: Carotid Solution Emerging Market Opportunity
Carotid Solution 10 Emerging Market Opportunity CGuard™ Embolic Prevention System Combines stent and embolic protection in a single device • Stent platform provides revascularization benefits • MicroNetacts as safety net by offering greater plaque scaffolding to prevent prolapse related to late embo
Slide 11: Positive CGuard Clinical Experience: CARENET
Positive CGuard™ Clinical Experience 11 * FIM , First in Man CARENET (CARotidEmbolic protection using microNET) FIM* Clinical Trial • 30 Patient Safety and Efficacy clinical trial • Prospective, multi-center, multispecialty, non-randomized single arm study • DWMRI follow ups at 48hrs and 30 days for
Slide 12: Positive CGuard Clinical Experience: PARADIGM
Positive CGuard™ Clinical Experience 12 * FIM , First in Man PARADIGM (Prospective evaluation of All-comer perRcutaneous cArotiD revascularization In symptomatic and increased-risk asymptomatic carotid artery stenosis using CGuard TM Mesh-covered embolic prevention system) PhysicianInitiatedAll-Come
Slide 13: Commercial Profile: Revenue Growth Driven by CGuard
Commercial Profile 13 Revenue Growth Driven by CGuard™ RX - 200 400 600 800 1,000 1,200 1,400 1,600 1,800 Q1 Q2 Q3 Q4 2012 2013 2014 2015
Slide 14: Strategic Distribution Partnership
Strategic Distribution Partnership 14 • Founded in 2005 as a Neurovascular company with a clinically-driven product development strategy • Reputation as the innovation leader in the neurovascular field • Extending success beyond stroke into the periphery and neurosurgical markets • Track record of c
Slide 15: Coronary MGuard EPS Improving AMI Patient Outcomes
Coronary MGuard™ EPS 15 Improving AMI Patient Outcomes • Current stents not specifically designed for AMI • Distal embolization occurs in up to 73% of cases* • Majority of AMI market is outside of the U.S. (~60%) • MGuardclinical experience including two randomized trials MASTER I and MASTER II with
Slide 16: MASTER I & II Pooled: All Cause Mortality
16 MASTER I & II Pooled: All Cause Mortality at 30 days (743 patients) 0 5 10 15 20 25 30 Time in Days BMS/DES (n=371) MGuard (n=372) 5 4 3 2 1 0 D e a t h ( % ) HR: 0.14 [95% CI: 0.02, 1.15] P=0.03 1.9% 0.3%
Slide 17: Robust Pipeline
Robust Pipeline 17 Commercial • CE Mark Cleared • 12-month MASTER I, II MicroNet™ Platform Technology MGuard™ Coronary EPS NVGuard™ Neurovascular* RGuard™ Renal* CGuard™ RX Carotid PVGuard™ Peripheral* MGuard™ Drug Eluting* *Planning & Development Phase Commercial • CE Mark Cleared • CARENET Tri
Slide 18: Neurovascular Market Opportunity
Neurovascular Market Opportunity 18 Innovation Leads Growth • Current designs have sub-optimal trackabilityand in vessel flexibility • MicroNetmeets need to simultaneously manage thrombosis of the aneurysmal sac while preserving the patency of the adjacent small vessels Source: MRG NeuroReport, Ev3
Slide 19: NVGuard Neurovascular Differentiation
NVGuard™ Neurovascular 19 Differentiation Yields Increased Utility Our Significant Advantage Over Existing Flow Diverters • MicroNetaperture & size • Low metal to artery ratio • Can be placed in side branches and bifurcations, which is impossible with current technology Total Aneurysm Market Value:
Slide 20: PVGuard Peripheral: The Embolic Prevention System
PVGuard™ Peripheral 20 The Embolic Prevention System A new stent category as the preferred solution for peripheral intervention • Current stents not specifically designed for embolic protection • Mesh covered stent category emerging as immediate opportunity • Strong global growth profile with increa
Slide 21: Target Milestones 2015E-2017E
2015E 2016E 2017E R&D/Clin/Reg Corporate Operational Commercial Target Milestones 21 Support & Execute on Growth Initiatives Strategic Partnership : Penumbra Strategic Partnership V Strategic Partnership IV DES Estimated CE Mark Achieve Targeted COGS NVGuardCE Mark Submission CGuard RX Launch NVGuar
Slide 22: Investment Summary
Investment Summary 22 • 2015 return to revenue growth driven by the full launch of carotid platform through strategic distribution partnership with Penumbra, Inc. • Operating and financial realignment inline with development and growth initiatives. • Advancing into highly valued Neuroand Peripheral
Slide 23: Contact: Alan Milinazzo, CEO; Craig Shore, CFO
Alan Milinazzo, CEO (888) 776-6804 alanm@inspiremd.com Craig Shore, CFO (888) 776-6804 craigs@inspiremd.com